Sol-Gel Technologies Ltd. (SLGL)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 17.3M | 400K | 696K | 108K |
| Operating Income | 11.2M | -6.3M | -3.4M | -3.9M |
| Net Income | 11.6M | -5.9M | -3.0M | -3.7M |
| Diluted EPS | $4.17 | $-2.13 | $nan | $-1.31 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 3.9M | 1.6M | 11.5M | 19.4M |
| Operating Income | -16.2M | -29.3M | -12.0M | -7.5M |
| Net Income | -14.9M | -27.2M | -10.6M | -6.1M |
| Diluted EPS | $-6.50 | $-10.01 | $-3.79 | $-2.19 |